Dr. Is In Sessions - World Medical Innovation Forum
WMIF Main Site

Dr. Is In Sessions

Dr. Is In Sessions

Tuesday, May 3, 2022

11:45 AM – 12:45 PM 3rd Floor and 7th Floor View Here
Dr. Is In

Lunch Sponsored by Astellas

Understanding long-term Gene and Cell Therapy investment complexities requires a keen awareness of where the science and the markets are headed. That’s why “The Doctor is In” in these updates on the latest GCT technologies. Presented by Mass General Brigham clinicians and innovators from the front lines of care, the sessions are co-hosted by expert analysts from Bank of America and include interactive discussion and Q&A.

  • Personalizing Cancer Care through RNA Therapies

    11:45 AM – 12:45 PM View Here

    In this session, Dr. Peruzzi will discuss how RNA for cancer therapy is a versatile of a tool for a protean problem.

    Jason Gerberry
    • Managing Director, Global Research, BofA Securities
    Pierpaolo Peruzzi, MD, PhD
    • Neurosurgeon and Principal Investigator, BWH
    • Assistant Professor of Neurosurgery, HMS
  • Designing for Success: Clinical Trial Approaches for Rare and Ultra-Rare Diseases

    11:45 AM – 12:45 PM View Here

    In this session, Dr. Vavvas will discuss examples of clinical trials in rare diseases and share insights into how clinical trials should be approached for rare and ultra-rare diseases and how study design is not a one-size fits all.

    Demetrios Vavvas, MD, PhD
    • Associate Director of the Retina Service, Mass Eye and Ear
    • Solman and Libe Friedman Professor of Ophthalmology, Co-Director Ocular Regenerative Medical Institute, HMS
  • A New Hope: Cell Therapy and Transplantation for Parkinson’s Disease

    11:45 AM – 12:45 PM View Here

    In this session, hear experts weigh in on the possibilities of cell therapy development and transplantation for the treatment of Parkinson’s Disease. What does the futures hold and how do we get there?

    Greg Harrison
    • Vice President, Global Research, BofA Securities
    Bob Carter, MD, PhD
    • Chairman, Department of Neurosurgery, MGH
    • William and Elizabeth Sweet Professor of Neurosurgery, HMS
    Todd Herrington, MD, PhD
    • Director, Deep Brain Stimulation Program, MGH
    • Assistant Professor of Neurology, HMS
    Kwang-Soo Kim, PhD
    • Director, Molecular Neurobiology Laboratory, McLean
    • Professor of Neuroscience and Psychiatry, HMS
    Jeffrey Schweitzer, MD, PhD
    • Neurosurgeon, MGH
    • Assistant Professor of Neurosurgery, HMS
  • The Inner Workings of Gene Therapy Manufacturing

    11:45 AM – 12:45 PM View Here

    In this session, Dr. Nikiforow will provide insights into the world of gene therapy manufacturing and the complexities of scaling, costs and insurance reimbursement.

    Michael Ryskin
    • Director, Global Research, BofA Securities
    Sarah Nikiforow, MD, PhD
    • Medical Director, Cell Manipulation Core Facility, Technical Director, Immune Effector Cell Therapy Program, DFCI
    • Assistant Professor, HMS
  • The Road Ahead: Regulatory Challenges for Gene and Cell Therapy

    11:45 AM – 12:45 PM View Here

    In this session, Dr. Marks will discuss the ins and outs of regulatory challenges for biological products and therapies in gene and cell therapy and the responsibility to assure safety and effectiveness.

    Geoff Meacham, PhD
    • Managing Director, Global Research, BofA Securities
    Peter Marks, MD, PhD
    • Director, Center for Biologics Evaluation and Research, FDA
  • The Mysterious Dark Genome

    11:45 AM – 12:45 PM View Here

    Dark genome, accounting for ~98.5% of the human genome and containing the non-coding part, offers unprecedented opportunity to look for novel elements that could play a role in human health. This non-coding region consists of repeat elements, enhancers, regulatory sequences and non-coding RNAs. This session will explore this exciting new frontier in biology and how to translate this so called “junk” and previously ignored genome into potential novel therapeutics.

    Angela Shen, MD
    • Vice President, Strategic Innovation Leaders, Mass General Brigham Innovation
    Richard Young, PhD
    • Professor, Whitehead Institute, MIT
    Rosana Kapeller, MD, PhD
    • Co-Founder, President & CEO, ROME Therapeutics
    Josh Mandel-Brehm
    • President & CEO, CAMP4 Therapeutics
    Amir Nashat, PhD
    • Managing Partner, Polaris Ventures
    Issi Rozen
    • Venture Partner, GV

the Future of Medicine and AI

May 11–13, 2020 | Boston, MA